颈项透明层超声在识别游离DNA筛查无法检出的罕见染色体异常中的效用
基于2009年3月至2012年12月加州产前筛查项目的回顾性队列研究,共452901名孕妇接受筛查,2572例染色体异常胎儿中1922例(74.7%)为cfDNA可检出的常见非整倍体。649例cfDNA无法检出的罕见非整倍体中108例(16.6%)NT≥3.0mm,NT≥3.0mm对该类异常的阳性预测值为2.6%,需筛查4176例胎儿才能检出1例罕见非整倍体。
要点
- 在cfDNA筛查基础上加做NT可检出16.6%的cfDNA无法检出的罕见非整倍体。
- NT≥3.0mm对罕见非整倍体的阳性预测值低,为2.6%。
- 需对4176例胎儿进行NT筛查才能检出1例罕见非整倍体。
核心结论
- 在cfDNA筛查基础上加做NT可检出16.6%的cfDNA无法检出的罕见非整倍体,但NT升高对罕见非整倍体的阳性预测值低,且需大量NT筛查才能检出每例受累胎儿。
研究设计与样本
- 回顾性队列研究,纳入2009年3月至2012年12月期间通过加州产前筛查项目筛查的孕妇,共452901名。
主要发现
- 2572例染色体异常胎儿中1922例(74.7%)为cfDNA可检出的常见非整倍体,剩余450979例无13、18、21三体。
- 450979例中4181例(0.93%)NT≥3.0mm。
- 649例cfDNA无法检出的罕见非整倍体中108例(16.6%)NT≥3.0mm。
- NT≥3.0mm对罕见非整倍体的阳性预测值为2.6%。
- 需筛查4176例胎儿才能检出1例罕见非整倍体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE:: To evaluate the utility of nuchal translucency (NT) screening in the detection of rare chromosomal aneuploidies in the setting of cell-free DNA (cfDNA). METHODS:: A retrospective cohort study of pregnancies screened through the California Prenatal Screening Program between March 2009 and December 2012. Karyotype analysis was the primary method of chromosomal evaluation during the study period and abnormal chromosomal karyotype results were classified by whether the abnormality would be detectable by cfDNA (non-mosaic trisomy 13, 18, 21 or sex-chromosomal aneuploidy (SCA)). For those rare aneuploidies detectable by karyotype but not cfDNA, the number of cases that had an increased NT and the detection rate and positive predictive value (PPV) of increased NT for rare aneuploidies were determined. RESULTS:: A total of 452,901 pregnant women had screening. There were 2,572 chromosomally abnormal fetuses, of which 1,922 (74.7%) had a common aneuploidy detectable by cfDNA, leaving 450,979 without T13, 18, 21. Of these, 4,181 (0.93%) had an NT ≥ 3.0mm. There were 649 rare aneuploidies not detectable by cfDNA. Of these, 108 (16.6%) had an NT ≥3.0mm. The PPV of an NT ≥3.0mm for rare aneuploidies was 2.6%. In all, 4,176 fetuses need to be screened with NT to detect a rare aneuploidy. CONCLUSIONS:: The addition of NT to cfDNA screening would detect 16.6% of rare aneuploidies. Increased NT has a low PPV for rare aneuploidies and a large number of women would need NT screening to detect each affected fetus. OBJECTIVE: To evaluate the utility of nuchal translucency (NT) screening in the detection of rare chromosomal aneuploidies in the setting of cell-free DNA (cfDNA). METHODS: A retrospective cohort study of pregnancies screened through the California Prenatal Screening Program between March 2009 and December 2012. Karyotype analysis was the primary method of chromosomal evaluation during the study period and abnormal chromosomal karyotype results were classified by whether the abnormality would be detectable by cfDNA (nonmosaic trisomy 13, 18, 21 or sex-chromosomal aneuploidy [SCA]). For those rare aneuploidies detectable by karyotype but not cfDNA, the number of cases that had an increased NT and the detection rate and positive predictive value (PPV) of increased NT for rare aneuploidies were determined. RESULTS: A total of 452 901 pregnant women had screening. There were 2572 chromosomally abnormal fetuses, of which 1922 (74.7%) had a common aneuploidy detectable by cfDNA, leaving 450 979 without T13, 18, 21. Of these, 4181 (0.93%) had an NT ≥3.0 mm. There were 649 rare aneuploidies not detectable by cfDNA. Of these, 108 (16.6%) had an NT ≥3.0 mm. The PPV of an NT ≥3.0 mm for rare aneuploidies was 2.6%. In all, 4176 fetuses need to be screened with NT to detect a rare aneuploidy. CONCLUSIONS: The addition of NT to cfDNA screening would detect 16.6% of rare aneuploidies. Increased NT has a low PPV for rare aneuploidies and a large number of women would need NT screening to detect each affected fetus.
引用
- Berger VK, Norton ME, Sparks TN, et al. The utility of nuchal translucency ultrasound in identifying rare chromosomal abnormalities not detectable by cell-free DNA screening. Prenat Diagn. 2019. PMID: 31652356. doi:10.1002/pd.5583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。